Mar 12 |
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
|
Mar 7 |
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
|
Mar 5 |
Gossamer Bio GAAP EPS of -$0.21 in-line
|
Mar 5 |
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
Feb 27 |
12 Best Medical Stocks to Buy Under $10
|
Jan 31 |
7 Micro-Cap Stocks That Could Majorly Surprise Investors
|
Dec 13 |
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
|
Dec 5 |
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Dec 5 |
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
|
Nov 29 |
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
|